Effectiveness of the low-molecular inductor of interferon of Amiksin® in treatment and preventive maintenance of the chronic recurrent inflammatory diseases of the upper respiratory tract

Introduction. In the formation of recurrent and/or prolonged chronic inflammatory diseases of the upper respiratory tract in addition to the known, previously studied, factors that play an important role in the violation of the human immune system at the level of local (mucosal) and systemic immunity and activation of herpes virus group (Epstein Virus Barr virus, cytomegalovirus, herpes simplex virus type 6). In the treatment of herpesvirus infections, activation of antiviral immunity in domestic medicine used drugs interferon inducer. Objective. To evaluate the efficacy of interferon inductor Amiksin® in patients with chronic recurrent inflammatory diseases of the upper respiratory tract. Materials and methods. Based on separation of “Allergy and Immunotherapy” SSC “Institute of Immunology” FMBA studied low-molecular interferon inductor Amixin® (JSC “Pharmstandard-Tomskhimpharm”, Russia) in the treatment of chronic recurrent inflammatory diseases of the upper respiratory tract. The study included 40 patients between men and women, aged 18 to 65years old with a history of recurrent chronic inflammatory diseases of the upper respiratory tract. Clinical research methods included a medical history, previous efficiency of the treatment, the presence of comorbidities. Laboratory methods include bacteriological crop on flora in the material from the oropharynx and the detection of DNA viruses of herpes group in saliva. Patients of the main group, after clinical and laboratory examination, prescribed therapy with Amixin®. Patients in both groups received symptomatic therapy. The total duration of observation of each patient was 3 months. Results. Amiksin® receiving the drug in patients with acute exacerbation of chronic recurrent upper respiratory tract inflammatory diseases contributed to a more rapid relief of general and local symptoms. Also it found that reduces performance Amiksin® average viral load against Epstein-Barr virus. Over the next 3 months follow-up, 25 % of patients the main group marked exacerbation study pathology of the upper respiratory tract, in the control group of patients with recurrent exacerbations were more - 60 %, indicating that preventive action Amiksin® therapy. Conclusions: The use of low-molecular interferon inductor Amiksin®(JSC “Pharmstandard-Tomskhimpharm”, Russia) in the combined therapy showed good efficacy in reducing the concentration of chronic viral infections in the oropharynx and prevention of chronic relapsing inflammatory diseases of the upper respiratory tract.

индуктор интерферона, иммунный ответ, хронические воспалительные заболевания верхних дыхательных путей, inductor of interferon, immune response, chronic inflammatory diseases of the upper respiratory tract

1. Бычкова Е.В. Клиническое значение современной диагностики в лечении латентных инфекций верхних дыхательных путей. Автореф. дис.. кан,д. мед. наук. СПб, 2008.

2. Смирнов В.С., Фрейдлин И.С. Иммунодефицитные состояния. СПб.: Фолиант, 2000.

3. Georgalas С.С., Tolley N.S., Narula A. Tonsillitis. BMJ Clinical Evidence. 2009;2009. pii: 0503. Review. PMID: 21718574.

4. Baron S. Medical Microbiology. Galveston (TX): University of Texas Medical Branch at Galveston, 1996. ISBN-10: 0-9631172-1-1.

5. Imbronito A.V., Grande S.R., Freitas N.M. et al. Detection of Epstein-Barr virus and human cytomegalovirus in blood and oral samples: comparison of three sampling methods. J Oral Sci 2008;50(1): 25-31. PMID: 18403880.

6. Wu R.Q., Zhang D.F., Tu E. et al. The mucosal immune system in the oral cavity an orchestra of T cell diversity. Int J Oral Sci-enc 2014;6:125-32. doi: 10.1038/ ijos.2014.48. PMID: 25105816.

7. Zuercher A.W., Coffin S.E., Thurnheer M.C. et al. Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J Immunol 2002;168(4):1796-803. PMID: 11823512.

8. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral Microbiol 2013;5. doi: 10.3402/jom. v5i0.20401. PMID: 23487566.

9. Williams J.E. Portal to the interior: viral pathogenesis and natural compounds that restore mucosal immunity and modulate inflammation. Alternative Medicine Review 2003;8(4):395-409. PMID: 14653767.

10. Шульженко А.Е. Стандартные и альтернативные подходы к диагностике и лечению герпесвирусных инфекций: Дис. докт. мед. наук. М., 2006.

11. Cowan D.L. Acute and chronic infection of the pharynx and tonsils. Scott-Brown’s Otolaryngology. Edd. D.L. Cowan, J. Hib-bert. 7th Ed. V.5. Chap. 4. Oxford, 1997:1-24.

12. Зубков М.Н. Алгоритм терапии острых и хронических инфекций верхних и нижних дыхательных путей. РМЖ 2009;17(2):123-31.

13. Рязанцев С.В. Этиопатогенетическая терапия острых фарингитов. Методические рекомендации. СПб., 2007.

14. Лопатин А.С. Лечение острого и хронического фарингита. РМЖ 2001; 9(16-17):58-61.

15. Медведев А.Ю., Валишин Д.А. Этиологические особенности ангин больных, инфицированных вирусом Эпштейна-Барр. Медицинский вестник Башкортостана 2011;6(3):88-90.

16. Шахгильдян В.И., Шипулина О.Ю., Сафонова А.П. и др. Клиническая интерпретация молекулярных методов в диагностике цитомегаловирусной инфекции. Доступно по: http://www.mter-labservice.ru/consulting/publications. php?id=8185&sphrase_id=71272

17. Свистушкин В.М., Мустафаев Д.М. Современные подходы к лечению и профилактике воспалительных заболеваний верхних отделов дыхательных путей. Consilium Medicum 2014;16(11):48-51.

18. Васяева А.А., Арефьева Н.А. Иммунотерапия при хронических фарингитах: показания, результаты. РМЖ 2010;18(30):1864-9.

19. Азнабаева Л.Ф., Арефьева Н.А. Иммунологические аспекты хронического тонзиллита. Вестник оториноларингологии 2013;(4):4-9.

20. Гофман В.Р., Смирнов B.C. Состояние иммунной системы при острых и хронических заболеваниях ЛОР-органов. В кн.: Иммунодефицитные состояния. Под ред. B.C. Смирнова, И.С. Фрейдлин. СПб.: Фолиант, 2000. С. 163-87.